Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities

Martina E Schmidt, Silke Hermann, Volker Arndt, Karen Steindorf, Martina E Schmidt, Silke Hermann, Volker Arndt, Karen Steindorf

Abstract

Background: Fatigue prevalence and severity have been assessed in a variety of studies, yet, not in a standardized way, and predominantly in breast cancer patients. Systematic, comparative investigations across a broad range of cancer entities are lacking.

Methods: The FiX study systematically enrolled 2244 cancer patients across 15 entities approximately 2 years after diagnosis. Fatigue was assessed with the multidimensional EORTC QLQ-FA12 questionnaire. Physical, emotional, cognitive, and total fatigue were compared across entities and with normative values of the general population. Differences in patients' characteristics and cancer therapy between entities were taken into account using analyses of covariance models.

Results: Across all entities, mean physical fatigue levels were significantly higher than age- and sex-matched means of the general population for all cancer entities (all Bonferroni-Holm adjusted P < .01). For most entities also emotional and cognitive fatigue levels were significantly higher than normative values. Age- and sex-standardized physical fatigue prevalence ranged from 31.8% among prostate to 51.7% among liver cancer patients. Differences between entities could not be fully explained by sex, age, BMI, or cancer therapy. Adjusted for these factors, mean physical fatigue was higher for stomach (P = .0004), lung (P = .034), kidney (P = .0011), pancreas (P = .081), and endometrium (P = .022) compared to breast cancer patients. Adjusted means of emotional fatigue were also lowest in breast cancer patients and significantly higher in stomach (P = .0047), bladder (P = .0036), and rectal (P = .0020) cancer patients.

Conclusions: Physical, emotional, and cognitive fatigue is prevalent in all 15 investigated cancer entities even 2 years after diagnosis. Fatigue in breast cancer patients, the so-far most studied group, is in the lowest range among all entities, suggesting that the extent of fatigue is still insufficiently determined. Entity-specific problems might need to be considered in the treatment of fatigue.

Keywords: breast cancer; cancer survivorship; cancer-related fatigue; gastrointestinal cancer; prevalence; quality of life.

Conflict of interest statement

None.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
CONSORT diagram
Figure 2
Figure 2
Box‐Whisker plots of raw physical, emotional, cognitive, and total fatigue scores. Boxes represents 25th to 75th percentiles with middle line in box at median, Whisker ends at 10th and 90th percentiles; red dots represent mean values. The median normative fatigue values of the German population of age 60+ years are presented by a blue line for males, and red line for females or both sexes, if median identical

References

    1. Hofman M, Ryan JL, Figueroa‐Moseley CD, Jean‐Pierre P, Morrow GR. Cancer‐related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4‐10.
    1. Schmidt ME, Chang‐Claude J, Vrieling A, Heinz J, Flesch‐Janys D, Steindorf K. Fatigue and quality of life in breast cancer survivors: temporal courses and long‐term pattern. J Cancer Surviv. 2012;6(1):11‐19.
    1. Bower JE. Cancer‐related fatigue–mechanisms, risk factors, and treatments. Nature Reviews Clinical Oncology. 2014;11(10):597‐609.
    1. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer‐related fatigue: a meta‐analysis. JAMA Oncology. 2017;3(7):961‐968.
    1. Network NCC . NCCN Clinical Practice Guidelines in Oncology: cancer‐related fatigue, version 2.2018. 2018.
    1. Wu C, Zheng Y, Duan Y, et al. Nonpharmacological interventions for cancer‐related fatigue: a systematic review and Bayesian network meta‐analysis. Worldviews Evid Based Nurs. 2019;16(2):102‐110.
    1. Singer S, Kuhnt S, Zwerenz R, et al. Age‐ and sex‐standardised prevalence rates of fatigue in a large hospital‐based sample of cancer patients. Br J Cancer. 2011;105(3):445‐451.
    1. Jones JM, Olson K, Catton P, et al. Cancer‐related fatigue and associated disability in post‐treatment cancer survivors. J Cancer Surviv. 2016;10(1):51‐61.
    1. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120(3):425‐432.
    1. Tan SY, Turner J, Kerin‐Ayres K, et al. Health concerns of cancer survivors after primary anti‐cancer treatment. Support Care Cancer. 2019;27(10):3739‐3747.
    1. Weis J, Tomaszewski KA, Hammerlid E, et al. International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ‐FA12). J Natl Cancer Inst. 2017;109(5):1‐8. 10.1093/jnci/djw273
    1. Weis J, Wirtz MA, Tomaszewski KA, et al. Sensitivity to change of the EORTC quality of life module measuring cancer‐related fatigue (EORTC QlQ‐Fa12): results from the international psychometric validation. Psycho‐oncology. 2019;28(8):1753‐1761.
    1. Hinz A, Weis J, Brahler E, Mehnert A. Fatigue in the general population: German normative values of the EORTC QLQ‐FA12. Qual Life Res. 2018;27(10):2681‐2689.
    1. Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2016;9:CD005001.
    1. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 2017;1:CD010802.
    1. Cobeanu O, David D. Alleviation of side effects and distress in breast cancer patients by cognitive‐behavioral interventions: a systematic review and meta‐analysis. J Clin Psychol Med Settings. 2018;25(4):335‐355.
    1. Schell LK, Monsef I, Wockel A, Skoetz N. Mindfulness‐based stress reduction for women diagnosed with breast cancer. Cochrane Database Syst Rev. 2019;3:CD011518.
    1. Hilfiker R, Meichtry A, Eicher M, et al. Exercise and other non‐pharmaceutical interventions for cancer‐related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect‐comparisons meta‐analysis. Br J Sports Med. 2018;52(10):651‐658.
    1. Campbell KL, Winters‐stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375‐2390.
    1. Zabernigg A, Giesinger JM, Pall G, et al. Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer. 2012;12:390.
    1. Hwang IC, Yun YH, Kim Y‐W, et al. Factors related to clinically relevant fatigue in disease‐free stomach cancer survivors and expectation‐outcome consistency. Support Care Cancer. 2014;22(6):1453‐1460.
    1. Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient‐reported outcomes of ECOG‐ACRIN E2805 trial. Support Care Cancer. 2018;26(6):1889‐1895.
    1. Ghatalia P, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: a meta‐analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015;95(2):251‐263.
    1. Li J, Sun W. Fatigue with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta‐analysis of randomized controlled trials. J Chemother. 2018;30(6–8):323‐331.
    1. Li CC, Tsai YF, Chang TC, Chen L. Associations among menopausal symptoms, sleep and fatigue in Taiwanese women with endometrial cancer. Eur J Cancer Care (Engl). 2017;26(5):e12559.
    1. Pham H, Torres H, Sharma P. Mental health implications in bladder cancer patients: a review. Urol Oncol. 2019;37(2):97‐107.
    1. Van Hemelrijck M, Sparano F, Josephs D, Sprangers M, Cottone F, Efficace F. Patient‐reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. BMC Urol. 2019;19(1):86.
    1. Nasvall P, Dahlstrand U, Lowenmark T, Rutegard J, Gunnarsson U, Strigard K. Quality of life in patients with a permanent stoma after rectal cancer surgery. Qual Life Res. 2017;26(1):55‐64.
    1. Downing A, Glaser AW, Finan PJ, et al. Functional outcomes and health‐related quality of life after curative treatment for rectal cancer: a population‐level study in England. Int J Radiat Oncol Biol Phys. 2019;103(5):1132‐1142.
    1. Hinz A, Weis J, Brahler E, Harter M, Geue K, Ernst J. Fatigue in cancer patients: comparison with the general population and prognostic factors. Support Care Cancer. 2020;28(9):4517‐4526.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj